Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions Post published:May 26, 2021 Post category:Press Release
Adding to their Expert Team, Albert Labs Announces the Formation and Chairs of its Two Advisory Boards Post published:May 25, 2021 Post category:Press Release
Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms Post published:May 25, 2021 Post category:Press Release
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease Post published:May 25, 2021 Post category:Press Release
Silo Pharma Submits Application for NASDAQ up-listing Post published:May 25, 2021 Post category:Press Release
Tryp Therapeutics Partners with Alcami for Proprietary Formulations Post published:May 25, 2021 Post category:Press Release
MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System Post published:May 24, 2021 Post category:Press Release
Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer Post published:May 21, 2021 Post category:Press Release
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms Post published:May 20, 2021 Post category:Press Release
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs Post published:May 20, 2021 Post category:Press Release